LA JOLLA, CALIF. - Sept. 11, 2018 - Promoting repair of dystrophic muscles is a major goal in the treatment of muscular dystrophies but is complicated by the incomplete knowledge of the cellular and molecular events that drive muscle regeneration.
Answers could lie in better understanding muscle repair--which resembles a delicate cellular dance choreographed by special cells called fibro-adipogenic progenitors (FAPs). Researchers already know these cells have a dark side--they are also responsible for the muscle wasting and scarring that occurs during Duchenne muscular dystrophy (DMD).
Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have revealed that FAPs don't have just one identity--but several distinct identities that emerge during key stages of muscle regeneration. Importantly, the FAPs that drive the symptoms of DMD have defined markers, meaning they could be targeted for drug development. The study was published in Nature Communications.
"There is increasing evidence from mouse studies that FAPs may play a critical role in muscle regeneration," says Grace Pavlath, Ph.D., senior vice president and scientific program director of the Muscular Dystrophy Association (MDA). "This study provides further insight into the mechanisms underpinning impaired regeneration and the development of fibrosis in DMD, and suggests future avenues for therapeutic intervention."
DMD mostly affects boys and is caused by the absence of a muscle-strengthening protein called dystrophin. Over time, muscle is replaced by scar tissue and fat, a process called fibrosis that ultimately leads to muscle wasting and weakness. Most people with DMD do not survive past their mid-20s.
"While advances are being made, there is still an urgent need for effective treatments for DMD," says Pier Lorenzo Puri, M.D., senior author of the study; professor in the Development, Aging and Regeneration Program at SBP; and lab director at Fondazione Santa Lucia IRCCS. "This discovery reveals novel cell targets for selective interventions that may promote regeneration and prevent fibrosis in DMD muscles."
Adds Filippo Buccella, founder of the Duchenne Parent Project Italy, part of an international federation created by parents to accelerate the development of new therapies, "This major advancement sheds a new light on the complex process of muscle degeneration/regeneration and may indeed improve the lives of Duchenne patients and their families. This breakthrough comes years after working with skilled physicians and great scientists like Dr. Puri, and it will be invaluable for the many patients and families who as of today are involved worldwide with experimental clinical trials."
Mapping FAPs over time
Puri's team analyzed the transcriptome of single FAP cells, which shows the genes that are turned on or off, from samples of muscle tissue obtained from mouse models of acute injury and DMD. This work identified cellular markers unique to a subpopulation of FAPs (sub-FAPs).
The scientists then applied the transcriptome analysis to each of the identified sub-FAPs to track the relative amounts of gene expression and types of genes expressed in three settings of muscle regeneration: following acute injury; during DMD; and immediately after birth, which uses a different regeneration process from adult muscle repair.
Clear patterns emerged and revealed that the identified sub-FAPs transitioned through different functional states--correlating with key events during the muscle regeneration process. At early stages after acute injury, sub-FAPs expressing the cell surface marker Tie2 appear. They were followed by transient sub-FAPs expressing the cell surface marker Vcam1. Genome-wide transcriptome analysis indicated that Tie2-expressing FAPs promote blood vessel formation and muscle stem cell activation, while Vcam1-expressing sub-FAPs promote fibrosis.
"Importantly, this analysis revealed an association between these functional states and the inflammatory response of regenerating muscles," says Puri. "We observed that during acute injury, the inflammatory infiltrate--specifically macrophages--promptly cleared Vcam1-expressing sub-FAPs. This restricts their pro-fibrotic activity to transient collagen deposition, which favors optimal muscle stem cell division. However, in experimental conditions of macrophage depletion or in DMD muscles, in which macrophage activity is altered, an impaired clearance of Vcam1-expressing sub-FAPs resulted in chronic deposition of collagen and muscle fibrosis--one of the most deleterious events in DMD progression."
Adds co-first author Barbora Malecova, Ph.D., former postdoctoral researcher in Puri's lab at SBP and current scientist at Avidity Biosciences, LLC, "This study elucidates the cellular and molecular pathogenesis of muscular dystrophy. These results indicate that removing or modulating the activity of Vcam1-positive sub-FAPs, which promote fibrosis, could be an effective treatment for DMD."
Additional co-first authors of the study are Sole Gatto, Ph.D. former postdoctoral researcher in Puri's lab at SBP and current bioinformatics scientist at Monoceros Biosystems, LLC; and Usue Etxaniz, Ph.D., postdoctoral fellow in Puri's lab at SBP.
"This work paves the way for pharmacological manipulation of FAPs, in order to correct their aberrant behavior in muscular diseases," says Puri. "For instance, the identification of drugs that can target Vcam1-expressing sub-FAPs might inspire therapeutic interventions toward preventing fibrosis in muscular dystrophies. It is also possible that existing drugs have this potential, and we are now exploring the effect of histone deacetylase (HDAC) inhibitors, which have shown beneficial effects (anti-fibrotic) in muscles of mouse models of DMD, in preclinical studies and in DMD boys in recent clinical trial."
Research reported in this press release was supported by National Institutes of Health (NIH) grants P30AR061303, R01AR056712, R01AR052779, and P30AR061303; California Institute for Regenerative Medicine (CIRM) grant TG2-01162; the Muscular Dystrophy Association (MDA), the French Muscular Dystrophy Association (AFM); and EPIGEN. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The study's DOI is 10.1038/s41467-018-06068-6.
About Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children's diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs nearly 900 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.